Cohance Lifesciences Limited (NSE:COHANCE)

Market Cap	145.95B
Revenue (ttm)	12.11B +26.0%
Net Income	1.77B -27.2%
EPS	6.88 -27.9%
Shares Out	382.57M
PE Ratio	55.46
Forward PE	31.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	547,407
Average Volume	712,903
Open	375.00
Previous Close	375.00
Day's Range	368.40 - 384.80
52-Week Range	368.40 - 1,328.00
Beta	0.45
RSI	13.91
Earnings Date	Feb 12, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 1,212
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: COHANCE

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.